Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Organs on chips Market
The global organs-on-chips market is projected to grow from USD 10.0 billion in 2025 to USD 18.8 billion by 2035 at a CAGR of 6.5%. This expansion is driven by the increasing demand for advanced drug discovery and toxicology testing methods that reduce reliance on animal models while improving accuracy and ethical compliance. Technological advancements in microfluidics and 3D bioprinting are enhancing the functionality of organ-on-chip systems, enabling more precise modeling of human physiology.
Pharmaceutical and biotechnology companies, along with academic and research institutes, are the primary adopters of these systems, leveraging their potential to accelerate drug development timelines and reduce costs. The market is characterized by a competitive landscape featuring key players such as Pfizer, Johnson & Johnson, and Merck, with North America leading in adoption due to robust research infrastructure and supportive regulatory policies.
Market size
Growth trajectory through 2035
Organs on chips Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Advancements in multi-organ chip systems
- Recent developments in multi-organ chip systems have enabled the simulation of interactions between different organ systems, enhancing the predictive accuracy of preclinical drug testing and reducing the risk of late-stage drug failures. These innovations are expected to drive broader adoption of organ-on-chip technologies in the pharmaceutical industry.
-
Development 02 Integration of AI and machine learning
- The integration of artificial intelligence and machine learning with organ-on-chip systems is improving data analysis capabilities, enabling more efficient and accurate interpretation of experimental results. This trend is fostering collaborations between organ-on-chip providers and AI/ML companies to develop next-generation drug discovery platforms.
-
Development 03 Expansion of applications in toxicology research
- Organ-on-chip technologies are increasingly being adopted for toxicology research, offering more accurate and ethical alternatives to traditional animal testing methods. This expansion is driven by regulatory pressures and the need for reliable data on drug safety and efficacy.
-
Development 04 Strategic partnerships and collaborations
- Recent collaborations between biotechnology firms, academic institutions, and technology providers are accelerating the development of advanced organ-on-chip systems. These partnerships are focused on addressing key challenges such as scalability, standardization, and regulatory approval, thereby driving market growth and innovation.
Emerging opportunities added
- Expansion into multi-organ models The development of multi-organ chip systems that can simulate interactions between different organ systems presents a significant opportunity to enhance the predictive accuracy of preclinical drug testing and reduce the risk of late-stage drug failures.
- Growing shift toward personalized medicine The increasing focus on personalized medicine is driving demand for organ-on-chip models tailored to individual patient profiles, offering opportunities for companies to develop customized solutions that address specific therapeutic needs.
- Integration with AI and machine learning for data analysis Leveraging artificial intelligence and machine learning to analyze data generated by organ-on-chip systems can improve the efficiency and accuracy of drug discovery processes, creating new avenues for market growth and innovation.
- Emerging markets in Asia-Pacific and Latin America Rapidly growing investments in biotechnology and life sciences in regions such as Asia-Pacific and Latin America are creating opportunities for organ-on-chip providers to expand their market presence and tap into new customer bases.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $10.00 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High costs associated with organ-on-chip development and implementation
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Advancements in multi-organ chip systems: Recent developments in multi-organ chip systems have enabled the simulation of interactions between different organ systems, enhancing the predictive accuracy of preclinical drug testing and reducing the risk of late-stage drug failures. These innovations are expected to drive broader adoption of organ-on-chip technologies in the pharmaceutical industry
+3 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 125-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Organs on chips Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- How do North America, Europe, Asia-Pacific, Middle East & Africa compare on market share, growth rate, and regulatory posture?
- Where do GSK plc, Pfizer Inc, Johnson & Johnson and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Regulatory and ethical emphasis on reducing animal testing) and top restraints (led by High costs associated with organ-on-chip development and im…), with quantified CAGR impact?
- What regulatory shifts and 4 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Regulatory and ethical emphasis on reducing animal testing Increasing regulatory and ethical pressures to minimize animal testing in pharmaceutical research are driving the adoption of organ-on-chip technologies, which offer more accurate and humane alternatives for preclinical drug development.
- Technological advancements in microfluidics and 3D bioprinting Innovations such as microfluidic systems and 3D bioprinting are enhancing the functionality and scalability of organ-on-chip models, enabling more precise replication of human organ systems and improving their applicability in drug discovery and toxicology research.
- Collaborative efforts across biotech, research institutions, and technology providers: Strategic partnerships between biotechnology firms, academic institutions, and technology specialists are fostering cross-disciplinary advancements, accelerating the development of more sophisticated organ-on-chip systems and broadening their adoption in the pharmaceutical and biotechnology …
- Increasing demand for personalized and precise medicine The shift toward personalized medicine is driving the need for organ-on-chip models that can accurately simulate individual patient responses, thereby improving therapeutic success rates and reducing the time and cost associated with drug development.
Restraints
Holding it back
- High costs associated with organ-on-chip development and implementation The complexity and cost of designing, fabricating, and maintaining organ-on-chip systems pose significant barriers to widespread adoption, particularly for small and mid-sized pharmaceutical and biotechnology companies.
- Technological complexities and scalability challenges While organ-on-chip technologies offer significant advantages, their development and scaling remain technically challenging, requiring specialized expertise and infrastructure that may limit market penetration in the near term.
- Limited standardization and regulatory frameworks The absence of standardized protocols and regulatory guidelines for organ-on-chip validation and approval creates uncertainty for end-users and may slow market growth until clearer frameworks are established.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory and ethical emphasis on reducing animal testing | +2.9% | Global | 2025–2035 |
| Technological advancements in microfluidics and 3D bioprinting | +1.8% | Global | 2025–2035 |
| Collaborative efforts across biotech, research institutions, and technology providers | +1.4% | Global | 2025–2035 |
| Increasing demand for personalized and precise medicine | +1.0% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High costs associated with organ-on-chip development and implementation | −1.2% | Global | 2025–2029 |
| Technological complexities and scalability challenges | −0.8% | Global | 2025–2029 |
| Limited standardization and regulatory frameworks | −0.6% | Global | 2025–2029 |
The organs-on-chips market is segmented by organ type, application, end user, and region. By organ type, the market includes liver, heart, lung, and other organ types, with liver and heart chips being among the most widely adopted due to their critical roles in drug metabolism and cardiotoxicity testing. Applications are divided into drug discovery, toxicology research, and others, with drug discovery representing the largest segment due to its direct impact on reducing time-to-market for new therapies. End users include pharmaceutical and biotechnology companies, academic and research institutes, and other organizations, with pharmaceutical companies leading in adoption due to their need for reliable preclinical models. Geographically, the market spans North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with North America holding the largest share due to its advanced research infrastructure and supportive regulatory environment.
Revenue share by type · 2025 base year
% OF $10.00 BN ORGANS ON CHIPS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $10.00 Bn Organs on chips Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $10.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~44.1% in 2025. North America dominates the organs-on-chips market, driven by a robust research infrastructure, significant investments in biotechnology, and proactive regulatory policies that support the adoption o…
Per-region detail
-
North America
North America dominates the organs-on-chips market, driven by a robust research infrastructure, significant investments in biotechnology, and proactive regulatory policies that support the adoption of advanced preclinical testing methods. The region's leadership is further reinforced by the presence of key market players and a high concentration of pharmaceutical and biotechnology companies
-
Europe
Europe is the second-largest market for organs-on-chips, characterized by strong academic and research institutions and increasing collaborations between industry and academia. The region's growth is supported by regulatory initiatives aimed at reducing animal testing and promoting the use of alternative methods in drug development
-
Asia-Pacific
The Asia-Pacific region is expected to exhibit the fastest growth rate during the forecast period, driven by rising investments in biotechnology, increasing government support for life sciences research, and a growing pharmaceutical industry. Countries such as China, Japan, and India are emerging as key contributors to market expansion in this region.Latin America and
-
Middle East & Africa
While these regions currently hold smaller market shares, they present significant growth opportunities due to improving healthcare infrastructure, increasing awareness of advanced drug testing methods, and rising investments in research and development. The adoption of organ-on-chip technologies in these regions is expected to accelerate as local industries and regulatory frameworks mature
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The organs-on-chips market is characterized by a competitive landscape featuring a mix of established pharmaceutical companies, specialized biotechnology firms, and innovative startups. Key players such as Pfizer, Johnson & Johnson, and Merck are leveraging organ-on-chip technologies to enhance their drug discovery and development processes, while specialized providers like Emulate, TissUse, and MIMETAS are driving innovation in chip design and functionality. Collaborations between industry and academic institutions are fostering cross-disciplinary advancements, enabling the development of more sophisticated and scalable organ-on-chip systems. The market's competitive dynamics are further shaped by strategic partnerships, mergers and acquisitions, and investments in research and development aimed at expanding the applications and capabilities of organ-on-chip technologies.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
GSK plc
Rank 01Share est. ~16%Revenue $38B FYHQ UK · London -
Pfizer Inc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Holding AG
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Novartis AG
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Merck & Co., Inc
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
AbbVie Inc
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Eli Lilly and Company
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
What is the expected CAGR in terms of revenue for the global organs on chips market over the forecast period (2020–2030)?
The global organs-on-chips market revenue is projected to expand at a CAGR of 30.76% during the forecast period. -
What was the global organs on chips market valued at in 2023?
The global organs on chips market was valued at USD 40.18 Million in 2023 -
Who are the key players in the organs on chips market?
The organs on chips market key players include TissUse GmbH, Allevi Inc., MIMETAS BV, Netri, BiomimX SRL, Elveflow, Altis Biosystems, Nortis Inc., InSphero, Emulate Inc. -
What are the factors driving the organs on chips market?
The rise in popularity of organs on chips due to their integration of microfluidics and tissue engineering. These technologies provide efficient solutions to persistent problems in the development of new medications and the treatment of certain diseases. The technique helps in research on drug development. Additionally, the market for organs on chips benefits from rising urbanization, lifestyle modifications, investments, and higher consumer expenditure. -
What are the different segments of the global organs on chips market?
The global organs on chips market is divided into organ type, application, end user, and region. -
Which region will lead the global organs on chips market?
Due to the availability of a wide range of help provided by important industry pros and an increase in the toxicological examination of medications on the many types of organ cells, North America now holds a monopoly on the organ-on-chip market.
The Organs on chips Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.